Mepolizumab: Phase III started

GlaxoSmithKline began the double-blind, placebo-controlled, European Phase III MEA115921 trial to evaluate 300 mg subcutaneous mepolizumab every 4 weeks for 52 weeks in about 130 relapsed or refractory patients receiving standard of care therapy, including background corticosteroid therapy with or without immunosuppressive therapy. GSK is conducting the trial as part of an agreement with NIH's National Institute of Allergy and Infectious Diseases (NIAID). Eosinophilic granulomatosis with polyangiitis is characterized by systemic vasculitis and eosinophilia and also known as Churg-Strauss syndrome. ...